| scholarly article | Q13442814 |
| P50 | author | Federico Piacentini | Q37839869 |
| Massimo Dominici | Q56849926 | ||
| P2093 | author name string | P F Conte | |
| E Barbieri | |||
| S Bettelli | |||
| G Ficarra | |||
| M V Dieci | |||
| V Guarneri | |||
| P2860 | cites work | Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 |
| Molecular portraits of human breast tumours | Q28032461 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution | Q29619477 | ||
| American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer | Q30494798 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases | Q34245828 | ||
| Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). | Q34613506 | ||
| Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells | Q34781692 | ||
| Gene expression profiles of primary breast tumors maintained in distant metastases | Q34793058 | ||
| Receptor conversion in distant breast cancer metastases | Q34989060 | ||
| Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss | Q35082619 | ||
| Breast cancer - one term, many entities? | Q35370118 | ||
| Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis | Q35583809 | ||
| Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors | Q35808400 | ||
| Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer | Q37240839 | ||
| Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? | Q37316222 | ||
| Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes | Q37457262 | ||
| Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer | Q37468681 | ||
| The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? | Q37807333 | ||
| Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry | Q42501389 | ||
| Impact of metastatic estrogen receptor and progesterone receptor status on survival | Q46382088 | ||
| Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management | Q46466675 | ||
| HER-2/neu expression in primary and metastatic breast cancer | Q46754911 | ||
| Should liver metastases of breast cancer be biopsied to improve treatment choice? | Q51054351 | ||
| Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. | Q54568017 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 101-108 | |
| P577 | publication date | 2012-09-20 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis | |
| P478 | volume | 24 |
| Q92610505 | ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer |
| Q26781177 | Biological markers of invasive breast cancer |
| Q37441159 | Breast Cancer Biomarkers: Utility in Clinical Practice |
| Q49796316 | Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. |
| Q35036174 | Can positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer?--A pilot study |
| Q90619966 | Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value |
| Q36085375 | Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients |
| Q53277939 | Cytologic assessment of estrogen receptor, progesterone receptor, and HER2 status in metastatic breast carcinoma. |
| Q38950545 | Detecting Tumor Metastases: The Road to Therapy Starts Here |
| Q38168792 | Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. |
| Q64072809 | Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India |
| Q33699614 | Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification? |
| Q41932946 | Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation |
| Q34834419 | Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis |
| Q54322784 | Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. |
| Q41716164 | Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer |
| Q35739831 | Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors |
| Q38842674 | Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review |
| Q47994905 | Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials |
| Q26780318 | HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach |
| Q64094297 | Hormone Receptors and Human Epidermal Growth Factor (HER2) Expression in Fine-Needle Aspirates from Metastatic Breast Carcinoma - Role in Patient Management |
| Q33779282 | Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers |
| Q48336597 | Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration. |
| Q37631461 | Immuno-PET for Clinical Theranostic Approaches |
| Q38298124 | Incorporation of biomarkers in phase II studies of recurrent glioblastoma |
| Q42506362 | Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. |
| Q92901350 | Ipsilateral breast tumor recurrence in early stage breast cancer patients treated with breast conserving surgery and adjuvant radiation therapy: Concordance of biomarkers and tumor location from primary tumor to in-breast tumor recurrence |
| Q39535768 | Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? |
| Q34130140 | Maintenance treatment of trastuzumab for patients with advanced breast cancer to achieve long term survival: two case reports and literature review |
| Q26748850 | Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells |
| Q48171311 | Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer |
| Q36266131 | Organ-specific isogenic metastatic breast cancer cell lines exhibit distinct Raman spectral signatures and metabolomes. |
| Q37316607 | Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis |
| Q38271031 | Pragmatic issues in biomarker evaluation for targeted therapies in cancer |
| Q64998084 | Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. |
| Q50619195 | Prognostic implications of receptor discordance between primary and recurrent breast cancer. |
| Q37687736 | Receptor conversion in metastatic breast cancer: a prognosticator of survival |
| Q38120666 | Relapsed triple-negative breast cancer: challenges and treatment strategies |
| Q38919700 | Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. |
| Q61800651 | SEOM clinical guidelines in advanced and recurrent breast cancer (2018) |
| Q50052578 | Significance of lung biopsy for the definitive diagnosis of lung nodules in breast cancer patients |
| Q90394455 | Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment |
| Q38209464 | Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives. |
| Q89883669 | The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients |
| Q91576551 | The effect of smoking on biological change of recurrent breast cancer |
| Q102388836 | The lingering mysteries of metastatic recurrence in breast cancer |
| Q55033826 | The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. |
| Q42544323 | Triple-negative breast cancer that progressed as estrogen receptor-positive skin metastases |
| Q33817285 | Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline |
| Q51304741 | Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis. |
Search more.